摘要
炎症性肠道疾病(IBD)中肠外表现(EIM)经常发生并且表现在IBD诊断的前后。他们最常影响眼睛、皮肤和关节,但也涉及到其他器官如肝脏。一些EIM与肠道疾病活性相关并且通过潜在IBD治疗改善。这在外周1型关节炎、口腔溃疡、虹膜外层炎和结节性红斑患者中可见。其他EIM是肠道疾病活动独立型,如葡萄膜炎和强制性脊柱炎。最后,一些EIM(例如坏疽性脓皮病和原发性硬化性胆管炎)与潜在IBD可能相关也可能不相关。EIM的成功治疗对改善IBD患者生活质量是重要的。肿瘤坏死因子抗体疗法对IBD的EIM是一个重要的治疗选择,然而至今还没有关于诸如vedolizumab的α4 β7 整合蛋白抗体有益效果被报道。本文综述了使用抗肿瘤坏死因子抗体的对IBD患者EIM的治疗经验。
关键词: 关节炎,肠外表现,炎症性肠病,葡萄膜炎
Current Drug Targets
Title:Biologics for Extraintestinal Manifestations of IBD
Volume: 15 Issue: 11
Author(s): Stephan R. Vavricka, Michael Scharl, Martin Gubler and Gerhard Rogler
Affiliation:
关键词: 关节炎,肠外表现,炎症性肠病,葡萄膜炎
摘要: Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Export Options
About this article
Cite this article as:
Vavricka R. Stephan, Scharl Michael, Gubler Martin and Rogler Gerhard, Biologics for Extraintestinal Manifestations of IBD, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125453
DOI https://dx.doi.org/10.2174/1389450115666140908125453 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers
Current Rheumatology Reviews Role of Prostaglandins in Multiple Sclerosis
Current Pharmaceutical Design The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Measures in Musculoskeletal Ultrasound. What are Valid?
Current Rheumatology Reviews Dietary Approaches and Alternative Therapies for Rheumatoid Arthritis
Current Nutrition & Food Science A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis
Current Drug Safety Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety